The standard of care for newly diagnosed hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative metastatic breast cancer is typically endocrine therapy in combination ...

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...

We offer targeted detection of a previously characterized mutation within the family. From a fresh EDTA blood sample, DNA is extracted directly and the target region is amplified and directly ...

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...

After a breast-cancer diagnosis and a separate scare, my mom tested for the BRCA2 gene mutation. Knowing it could be hereditary, I decided to get tested at 23 to see if I also carried the mutation. My ...

Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Gila Pfeffer is a humor writer who splits her time between NYC and London. The following is an adapted excerpt from her memoir, "Nearly Departed: Adventures in Loss, Cancer, and Other Inconveniences." ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Genetic testing can confirm a muscular dystrophy (MD) diagnosis when symptoms and other tests already suggest MD. It also identifies specific gene mutations that can guide targeted treatment. Genetic ...